JP6105631B2 - １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法 - Google Patents
１，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法 Download PDFInfo
- Publication number
- JP6105631B2 JP6105631B2 JP2014556029A JP2014556029A JP6105631B2 JP 6105631 B2 JP6105631 B2 JP 6105631B2 JP 2014556029 A JP2014556029 A JP 2014556029A JP 2014556029 A JP2014556029 A JP 2014556029A JP 6105631 B2 JP6105631 B2 JP 6105631B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- tautomer
- protecting group
- group selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000707 stereoselective effect Effects 0.000 title claims description 8
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000003786 synthesis reaction Methods 0.000 title description 4
- CGBQPXGVSMMBHA-UHFFFAOYSA-N 9-hydroxy-1,4-diazaspiro[5.5]undecan-5-one Chemical compound C1CC(O)CCC21C(=O)NCCN2 CGBQPXGVSMMBHA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 21
- 150000003839 salts Chemical group 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 239000000543 intermediate Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 0 *NCCN(*)C([C@](CC1)CC[C@@]1O)=O Chemical compound *NCCN(*)C([C@](CC1)CC[C@@]1O)=O 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- -1 2,2,2-trifluoro-acetyl Chemical group 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- YELXTWKVTZTDCM-UHFFFAOYSA-N pentadecan-3-one Chemical compound CCCCCCCCCCCCC(=O)CC YELXTWKVTZTDCM-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000011916 stereoselective reduction Methods 0.000 description 2
- YVHYGXQIVMKZPL-UHFFFAOYSA-N 1-(2,2,2-trifluoroacetyl)-1,4-diazaspiro[5.5]undecane-5,9-dione Chemical compound FC(F)(F)C(=O)N1CCNC(=O)C11CCC(=O)CC1 YVHYGXQIVMKZPL-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- WDWUSIRRAZAUFK-UHFFFAOYSA-N 9-(2,2,2-trifluoroacetyl)-1,4-dioxa-9,12-diazadispiro[4.2.5^{8}.2^{5}]pentadecan-13-one Chemical compound FC(F)(F)C(=O)N1CCNC(=O)C11CCC2(OCCO2)CC1 WDWUSIRRAZAUFK-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- VTEYPFDZDDEZTB-UHFFFAOYSA-N CC(C)(C)C(CNC(C1(CC2)CCC2=O)=O)N1C(C(F)(F)F)=O Chemical compound CC(C)(C)C(CNC(C1(CC2)CCC2=O)=O)N1C(C(F)(F)F)=O VTEYPFDZDDEZTB-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- IPSGFPBMDIFDNY-UHFFFAOYSA-N tert-butyl 5,9-dioxo-1-(2,2,2-trifluoroacetyl)-1,4-diazaspiro[5.5]undecane-4-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCN(C(=O)C(F)(F)F)C11CCC(=O)CC1 IPSGFPBMDIFDNY-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CIVIMXHPZIVNEG-UHFFFAOYSA-N undecane-3,7-dione Chemical compound CCCCC(=O)CCCC(=O)CC CIVIMXHPZIVNEG-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12154688.1 | 2012-02-09 | ||
| EP12154688 | 2012-02-09 | ||
| PCT/EP2013/052287 WO2013117568A1 (de) | 2012-02-09 | 2013-02-06 | Verfahren zur stereoselektiven synthese von 1,4-geschützten 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecane |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506966A JP2015506966A (ja) | 2015-03-05 |
| JP2015506966A5 JP2015506966A5 (enExample) | 2016-03-24 |
| JP6105631B2 true JP6105631B2 (ja) | 2017-03-29 |
Family
ID=47678813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556029A Active JP6105631B2 (ja) | 2012-02-09 | 2013-02-06 | １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8629146B2 (enExample) |
| EP (1) | EP2812317B1 (enExample) |
| JP (1) | JP6105631B2 (enExample) |
| KR (1) | KR20140128318A (enExample) |
| CN (1) | CN104080775A (enExample) |
| AU (1) | AU2013218119A1 (enExample) |
| BR (1) | BR112014019196A8 (enExample) |
| CA (1) | CA2862520A1 (enExample) |
| CL (1) | CL2014001823A1 (enExample) |
| EA (1) | EA201400882A1 (enExample) |
| IL (1) | IL233370A (enExample) |
| MX (1) | MX2014009033A (enExample) |
| PH (1) | PH12014501760A1 (enExample) |
| WO (1) | WO2013117568A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575507A (en) * | 1985-05-29 | 1986-03-11 | Pfizer Inc. | Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use |
| ATE557008T1 (de) | 2002-03-30 | 2012-05-15 | Boehringer Ingelheim Pharma | 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| CA2631813A1 (en) | 2005-12-12 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof |
| PT2245026E (pt) | 2008-02-07 | 2012-10-15 | Boehringer Ingelheim Int | Heterociclos espirocíclicos, produtos farmacêuticos contendo estes compostos, sua utilização e processo para a sua preparação |
| EP2289881A1 (de) | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
| PE20141012A1 (es) * | 2011-02-01 | 2014-09-10 | Boehringer Ingelheim Int | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion |
-
2013
- 2013-02-06 JP JP2014556029A patent/JP6105631B2/ja active Active
- 2013-02-06 KR KR1020147021922A patent/KR20140128318A/ko not_active Withdrawn
- 2013-02-06 EP EP13703045.8A patent/EP2812317B1/de active Active
- 2013-02-06 CA CA2862520A patent/CA2862520A1/en not_active Abandoned
- 2013-02-06 MX MX2014009033A patent/MX2014009033A/es not_active Application Discontinuation
- 2013-02-06 WO PCT/EP2013/052287 patent/WO2013117568A1/de not_active Ceased
- 2013-02-06 EA EA201400882A patent/EA201400882A1/ru unknown
- 2013-02-06 BR BR112014019196A patent/BR112014019196A8/pt not_active IP Right Cessation
- 2013-02-06 CN CN201380006918.0A patent/CN104080775A/zh active Pending
- 2013-02-06 AU AU2013218119A patent/AU2013218119A1/en not_active Abandoned
- 2013-02-07 US US13/761,211 patent/US8629146B2/en active Active
-
2014
- 2014-06-25 IL IL233370A patent/IL233370A/en not_active IP Right Cessation
- 2014-07-09 CL CL2014001823A patent/CL2014001823A1/es unknown
- 2014-08-05 PH PH12014501760A patent/PH12014501760A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2812317B1 (de) | 2016-02-03 |
| BR112014019196A8 (pt) | 2017-07-11 |
| PH12014501760B1 (en) | 2014-11-10 |
| US8629146B2 (en) | 2014-01-14 |
| BR112014019196A2 (enExample) | 2017-06-20 |
| WO2013117568A1 (de) | 2013-08-15 |
| EP2812317A1 (de) | 2014-12-17 |
| CN104080775A (zh) | 2014-10-01 |
| CA2862520A1 (en) | 2013-08-15 |
| US20130211081A1 (en) | 2013-08-15 |
| EA201400882A1 (ru) | 2015-01-30 |
| KR20140128318A (ko) | 2014-11-05 |
| AU2013218119A1 (en) | 2014-07-17 |
| IL233370A (en) | 2015-04-30 |
| IL233370A0 (en) | 2014-08-31 |
| PH12014501760A1 (en) | 2014-11-10 |
| MX2014009033A (es) | 2014-10-17 |
| CL2014001823A1 (es) | 2015-03-06 |
| JP2015506966A (ja) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7386855B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造 | |
| AU2018102141A4 (en) | Method for preparing Baricitinib | |
| CN107474107B (zh) | Glyx-13的制备方法及用于制备glyx-13的化合物 | |
| CN105541891A (zh) | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 | |
| EP2107059A1 (en) | Conversion of tryptophan into ß-carboline derivatives | |
| JP6105631B2 (ja) | １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法 | |
| WO2020108415A1 (zh) | 一种trk激酶抑制剂化合物的中间体化合物及制备方法 | |
| CN113614069B (zh) | 用于制备(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺或其盐的方法以及使用其制备托法替尼的方法 | |
| CN108727224B (zh) | 药物合成用中间体的制备方法 | |
| CN107459524B (zh) | 一种双氮氧杂环螺二酮哌嗪骨架类化合物及其构建方法 | |
| CN110963959B (zh) | 一种合成n-保护及非保护的3-羟基-4,4-二甲基哌啶的制备方法 | |
| JP5009736B2 (ja) | 環状アミノエーテルを用いたマンニッヒ反応 | |
| JP2011522042A (ja) | タダラフィルの製造方法 | |
| CN103254194B (zh) | 一种8-硫杂黄嘌呤化合物的制备方法 | |
| CN1989097A (zh) | 用于制备非对映异构体富集的化合物的方法 | |
| JPH02290851A (ja) | ２―クロロ―５―アミノメチルーピリジンの製造方法 | |
| JP7778129B2 (ja) | リジン特異的デメチラーゼ１（ｌｓｄ１）阻害剤の製造方法 | |
| JP7536950B2 (ja) | プロリンアミド化合物の製造方法 | |
| ES2606909T3 (es) | Método para sintetizar aminoalcoholes | |
| CN113087649B (zh) | 一种二氢吡咯酮衍生物的制备方法 | |
| CN110862325B (zh) | 一种(1r,3s)-3-氨基-1-环戊醇及其盐的制备方法 | |
| CN107151239A (zh) | 一种合成α‑1,3‑二噻烷取代醛类化合物的方法 | |
| CN104311473A (zh) | 一种哌啶类化合物及其制备方法 | |
| CN114105961A (zh) | 一种ido1抑制剂(ly-3381916)制备方法 | |
| KR100574343B1 (ko) | 입체선택적 4-하이드록시-2-피페리디논의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170201 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170302 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6105631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |